🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Debate 2: The Case for Focal External Beam Radiation Therapy Boost Ove... sciencedirect.com/science/articl… Nice debate/discussion on a question that comes up every week - brachy boost vs microboost Tyler Seibert MD PhD American Brachy ARRO ACROresident #whereisHoskin

Thanks Sophia Kamran, MD & Constantinos Zamboglou for this invitation to highlight keypoints and thoughts about ADT and Post-op RT. sciencedirect.com/science/articl… ✨✨✨✨✨✨✨✨✨✨

Happy to share our review on hypo- and ultra-hypofractionation for prostate cancer radiotherapy, just published in Seminars in Radiation Oncology Full-text authors.elsevier.com/a/1lFrI3lXQoc1… Harshani Green 💙 @harshanigreen.bsky.social Alison Tree 💙 The Royal Marsden NHS Foundation Trust The ICR Elsevier Oncology Advance

Primary CNS Lymphoma: fRT Vs WBRT N=151 /8 Centres WBRT(123pts) 18-45(Median 35.7 Gy) fRT(28pts) 25Gy/5# or 40Gy/20# Median OS was longer in patients who received fRT Vs WBRT (67.6 versus 20.1 months) Focal RT appears promising and needs Prospective evaluation on Ph III

‼️ PACE-C RCT Prostate cancer -> 60 Gy/20 fx vs 36.25 Gy/5 fx Grade 2+ CTCAE GI toxicity: 10% vs 17% favoring 20 fx, p=0.0011 Grade 2+ CTCAE GU toxicity: 28% vs 34% favoring 20 fx, p=0.050 Why do a more toxic regimen with 5 fx? 👎 👎 👎

Congratulations tabassum wadasadawala & TMC Radiation Oncology TMC Breast DMG Shraddha Kenekar Revathy Krishnamurthy Rima Pathak MD Rajiv Sarin MD for publishing the largest Real World data on cosmetic outcomes after ultra-hypofractionated whole breast RT with SIB! 📄 Now online in IJROBP - The Red Journal 🔗 doi.org/10.1016/j.ijro…

NO ASSOCIATION BETWEEN PREPROCEDURAL FASTING AND WITNESSED PULMONARY ASPIRATION A SYSTEMATIC REVIEW AND META-ANALYSIS I want to bring to everyone's attention the publication of an article we have been working on for some time. Ever been annoyed by having cases cancelled because

🎉 Congratulations to the 2025–2026 ABS Board of Directors and Officers! Your leadership will shape the future of brachytherapy, and we’re excited for what’s ahead. 💙 DrKamrava Peter Rossi marisa kollmeier #Brachytherapy #ThisisBrachytherapy #BrachytherapyLeadership

💥 PEACE-V STORM final results at #ESTRO25: ENRT beats MDT for oligorecurrent nodal prostate cancer. ✔️ Better MFS (76% vs. 63%) ✔️ Improved control ✔️ Similar toxicity, fewer treatments 👉 bit.ly/46bHU6N Piet Ost Thomas Zilli

Join us in celebrating the remarkable achievements of our 2025 #ABSFellows. These exceptional individuals are the epitome of brilliance, passion, and commitment to making a positive impact in the field of #brachytherapy. Tim Showalter Parag Sanghvi MD MSPH UC San Diego Rad Med UVA School of Medicine

#ActiveSurveillance for #ProstateCancer in Göteborg-1 Trial ⏩️25 years FU ✨Failure-free survival rate at 22 yr: 68% ✨PC-specific survival rate at 25 yr: 94% ✨PC-specific survival rate at 24 yr: - 99% for very-low-risk - 92% for low-risk - 85% for intermediate-risk

Congrats @DrMiraKeyes and many Canadian who contributed. American Brachy Joint ABS/GEC-ESTRO Consensus Statement on the objectives of training ... sciencedirect.com/science/articl…

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C) thelancet.com/journals/lanon… The phase 3 PACE-C trial compared early toxicity between moderately hypofractionated radiotherapy (MHRT) and stereotactic body

Check out our latest work on T cell dynamics in response to RT including data from patients nature.com/articles/s4146…

Local radiotherapy doesn’t improve OS in mHSPC patients, but significantly prolongs time to ADT resistance. Redefining selection criteria is key to identify those who truly benefit in the era of next-generation imaging and modern systemic therapies. sciencedirect.com/science/articl…

Brief 🧵 1/ How common is *failure* of modern active surveillance (AS) for #ProstateCancer (PCa)? Which patients are at higher risk? Spoiler 🚨: it’s pretty simple European Urology Oncology @UroToday OncoAlert PCF Science GU Cast | Urology podcast! Amer. Urol. Assn. European Association of Urology (EAU)

In high-risk prostate cancer, radiotherapy plus ADT significantly reduces the risk of distant metastasis compared to surgery-based approaches. However, post-metastasis survival does not differ between treatments. European Urology Oncology Daniel E Spratt OncoAlert Advanced Prostate Cancer Consensus Conference European Association of Urology (EAU)

Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis europeanurology.com/article/S0302-… Meta-analysis of 19 observational studies involving up to 118,830 patients with clinically localized #ProstateCancer found that treatment with

DADSPORT meta-analysis investigated ADT in post-op RT for nonmet prostate cancer ➡️Short or long ADT after postop RT ⬆️ MFS and PCSS. ➡️No clear benefits of OS when ADT is added. ➡️Potential benefit of ADT on OS confined to pts with higher pre-RT PSA sciencedirect.com/science/articl…

High-dose-rate (HDR) brachytherapy boost in combination with external ... sciencedirect.com/science/articl… An update on data for HDR boost for prostate cancer American Brachy ARRO ACROresident Peter Rossi marisa kollmeier Special thanks to Sagar Patel!